Sertraline Tops CBT for Reducing Depression in Dialysis Patients
TUESDAY, Feb. 26, 2019 -- For patients receiving maintenance hemodialysis, an engagement interview on treatment acceptance has no effect on acceptance of depression treatment, and depression scores are modestly better with sertraline treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 26, 2019 Category: Pharmaceuticals Source Type: news
Treatment of depression for people with end-stage kidney disease undergoing hemodialysis
(Source: NIDDK News)
Source: NIDDK News - February 26, 2019 Category: Endocrinology Source Type: news
FTC gives the go ahead to Fresenius, NxStage merger
The U.S. Federal Trade Commission said yesterday that it cleared Fresenius (NYSE:FMS) in its $2 billion acquisition of NxStage Medical (NSDQ:NXTM).
As part of the approval, NxStage will have to part ways with its bloodline tubing set business, offloading them to B. Braun, according to the regulatory agency.
The vote to approve the merger was split, however, with Republicans Joseph Simons, Noah Phillips and Christine Wilson voting to approve while Democrats Rohit Chopra and Rebeca Slaughter dissented.
The FTC said that it had previously filed a complaint suggesting that the merger would harm competition for bloodline tubi...
Source: Mass Device - February 20, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Dialysis Featured Mergers & Acquisitions Fresenius NxStage Medical Inc. Source Type: news
Becton Dickinson wins FDA 510(k) for Wavelinq 4F endoAVF system
Becton Dickinson (NYSE:BDX) said today that it won FDA 510(k) clearance for its WavelinQ 4 French endovascular arteriovenous fistula creation system.
The Franklin Lakes, N.J.-based company said that the newly cleared WavelinQ 4F endoAVF system features improved technology that allows for the creation of an AVF in either the ulnar artery and ulnar vein or the radial artery and radial vein.
The new ability expands upon the company’s existing indications for its WavelinQ 6F endoAVF system, BD said.
“With BD WavelinQ 4F endoAVF system, I can provide my ESRD patients with two additional fistula location options co...
Source: Mass Device - February 13, 2019 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Featured Food & Drug Administration (FDA) Regulatory/Compliance Vascular bectondickinson Source Type: news
Effects of Vadadustat on Hemoglobin in Hemodialysis Patients Effects of Vadadustat on Hemoglobin in Hemodialysis Patients
Vadadustat is a potential new treatment for anemia in chronic kidney disease -- but what do we know about its impacts in patients receiving hemodialysis?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2019 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Fresenius launches 2008T BlueStar hemodialysis machine in U.S.
Fresenius Medical Care (NYSE:FMS) said today that it launched its 2008T BlueStar hemodialysis machine, touting more than 30 improvements from previous device models.
The Waltham, Mass.-based company said that the new system is intended to allow for simpler operation and maintenance with additional treatment options, and added that the system features a number of newly automated technologies.
“The new and enhanced 2008T BlueStar hemodialysis machines provide more than 30 unique enhancements to better serve end stage renal disease patients undergoing dialysis. Our new machines represent a significant step forward for...
Source: Mass Device - February 11, 2019 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Dialysis Fresenius Source Type: news
Fresenius Medical Care North America Launches 2008T BlueStar(TM) Hemodialysis Machine Across the U.S.
Fresenius Medical Care North America Advances Renal Care with Next Generation Dialysis Delivery System Featuring More Than 30 Enhancements
WALTHAM, Mass., Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- Fresenius Medical Care North America's... Devices, Product Launch Fresenius Medical Care, 2008T BlueStar, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news
Hemodialysis Facility Practices Linked to Patient Outcomes
TUESDAY, Feb. 5, 2019 -- Certain practices in hemodialysis facilities relating to management of fluid volume and intradialytic hypotension are associated with patient outcomes, according to a study published online Feb. 5 in the Clinical Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 5, 2019 Category: Pharmaceuticals Source Type: news
Behind the Invention: Wearable Artificial Kidney
If you've ever known someone who has had to be on dialysis, you know that the quality of life for dialysis patients is not great.
First of all, there is a pill burden.
"My patients need to eat 20 to 30 pills a day,"Â Victor Gura, MD, an internist, nephrologist, and inventor of the Wearable Artificial Kidney (WAK) told MD&M West attendees on Tuesday. "So one was making a joke. He said 'I could put them in a bowl with some dressing and have a salad'. The bottom line is it's a burden and it's also expensive."
In addition to the pill burden, dialysis patients are restricted in the amount of water and...
Source: MDDI - February 5, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: R & D Design Source Type: news
Peritoneal dialysis cost saving versus haemodialysis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news
Fruit, Vegetable Intake Very Low in Hemodialysis Population
THURSDAY, Jan. 31, 2019 -- Fruit and vegetable intake is very low in the hemodialysis population, with higher consumption associated with lower mortality, according to a study published online Jan. 31 in the Clinical Journal of the American Society... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2019 Category: Pharmaceuticals Source Type: news
Another Device Gets Added to the Peritoneal Dialysis Mix
AWAK Technologies has been granted a breakthrough device designation from FDA for a wearable and ultra-portable peritoneal dialysis (PD) device.
The Singapore-based company’s AWAK PD device allows dialysis to be performed "on-the-go", overcoming the challenge of long hours of therapy and connection to large-size dialysis machines, currently faced by renal patients.
The company said FDA’s designation was granted after reviewing the results from the First-In-Human safety trial of AWAK PD device, which was successfully completed in October 2018 at the Singapore General Hospital, Singapore's...
Source: MDDI - January 11, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients
A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, approved in the U.S. and elsewhere for HIV-1-infected patients with mild-to-moderate chronic kidney disease, may also work well in those with end-stage renal disease on chronic hemodialysis, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests
Alfacalcidol did not reduce the risk for cardiovascular events in patients without secondary hyperparathyroidism who were undergoing maintenance hemodialysis, the J-DAVID trial found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Nephrology News Source Type: news
Vitamin D Analogue No Help for CV Prevention in Hemodialysis Patients
(MedPage Today) -- Trial limited to patients without secondary hyperparathyroidism (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 13, 2018 Category: Urology & Nephrology Source Type: news
